Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial

Blood (2024) 144 (Supplement 1): 224.

https://doi.org/10.1182/blood-2024-201694

Published: 2024

Journal Articles

4D intravital imaging studies identify platelets as the predominant cellular procoagulant surface in a mouse hemostasis model

Abigail Ballard-Kordeliski, Robert H. Lee, Ellen C. O’Shaughnessy, Paul Y. Kim, Summer R. Jones, Rafal Pawlinski, Matthew J. Flick, David S. Paul, Nigel Mackman, David A. Adalsteinsson, Wolfgang Bergmeier

Blood (2024) 144 (10): 1116–1126.

https://doi.org/10.1182/blood.2023022608

Published: 2024

Includes: Multimedia, Supplemental data

Journal Articles

A Lenalidomide-Inducible Suicide Switch for Gene- and Cell-Based Therapy

William Lin, Ditsa Sarkar, Joanna Y Kim, Nelson H Knudsen, Isabel C Lane, Andi Cheng, Gabriele Kembaun, Tamina Kienka, Jeannie Carreiro, Amanda A Bouffard, Marcela V Maus, Robert T Manguso, Max Jan

Blood (2023) 142 (Supplement 1): 4825.

https://doi.org/10.1182/blood-2023-189628

Published: 2023

Journal Articles

Targeting Normal Myelopoiesis Negatively Affects CAR T Cell Activity

Miriam Y Kim, Matthew L. Cooper, Julie K. Ritchey, Julie O'Neal, John DiPersio

Blood (2023) 142 (Supplement 1): 2077.

https://doi.org/10.1182/blood-2023-186015

Published: 2023

Journal Articles

An “Off-the-Shelf” CD2 Universal CAR-T Therapy Combined with a Long-Acting IL-7 for T-Cell Malignancies

Jingyu Xiang, Jessica Devenport, Alun J Carter, Karl Staser, Michael P. Rettig, Miriam Y Kim, Julie O'Neal, Julie K. Ritchey, Feng Gao, Garrett Rettig, Rolf Turk, Alexandra Wolfarth, Byung Ha Lee, Matthew L. Cooper, John F. DiPersio

Blood (2023) 142 (Supplement 1): 764.

https://doi.org/10.1182/blood-2023-181087

Published: 2023

Journal Articles

CXCR4 to improve both T cell homing and function

Miriam Y. Kim

Blood (2023) 141 (21): 2546–2547.

https://doi.org/10.1182/blood.2023020050

Published: 2023

Journal Articles

Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells

Joseph C. Rimando, Ezhilarasi Chendamarai, Michael P. Rettig, Reyka Jayasinghe, Matthew J. Christopher, Julie K. Ritchey, Stephanie Christ, Miriam Y. Kim, Ezio Bonvini, John F. DiPersio

Blood (2023) 141 (14): 1718–1723.

https://doi.org/10.1182/blood.2022017795

Published: 2023

Includes: Supplemental data

Journal Articles

Reticulocytes Are an Unappreciated Risk Factor for RBC Alloimmunization at the Donor and Recipient Levels

Tiffany Thomas, Annie Qiu, Christopher Y Kim, Dominique E Gordy, Anabel Miller, Maria Tredicine, Elizabeth Stone, Monika Dzieciatkowska, Eldad A. Hod, Angelo D'Alessandro, Steven L Spitalnik, James C Zimring, Imo J Akpan, Chance John Luckey, Krystalyn E Hudson

Blood (2022) 140 (Supplement 1): 75–76.

https://doi.org/10.1182/blood-2022-169746

Published: 2022

Journal Articles

Normal Myeloid Cells Are Required for Sustained CAR T Cell Activity Against Myeloid Tumor in a Humanized Mouse Model

Miriam Y Kim, Matthew L Cooper, Julie K Ritchey, Julia Hollaway, John F. DiPersio

Blood (2021) 138 (Supplement 1): 734.

https://doi.org/10.1182/blood-2021-150935

Published: 2021

Journal Articles

A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma

Blood (2021) 137 (5): 600–609.

https://doi.org/10.1182/blood.2020006578

Published: 2021

Includes: Supplemental data

Journal Articles

CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas

Blood (2020) 136 (20): 2308–2318.

https://doi.org/10.1182/blood.2020006619

Published: 2020

Includes: Supplemental data

Journal Articles

Flotetuzumab and Other Cellular Immunotherapies Upregulate MHC Class II Expression on Acute Myeloid Leukemia Cells in Vitro and In Vivo

Joseph Rimando, MD, Michael P. Rettig, PhD, Matt Christopher, MD PhD, Julie K Ritchey, Miriam Y Kim, MD, John Muth, MS, Jan Davidson, John F. DiPersio, MD PhD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-133891

Published: 2020

Journal Articles

Chimeric Antigen Receptor T Cells Specific for CLL-1 for Treatment of Acute Myeloid Leukemia

Elisa De Togni, BA, Miriam Y Kim, MD, Matt L Cooper, PhD, Julie Ritchey, Julie O'Neal, PhD, Jessica Niswonger, John F. DiPersio, MD PhD

Blood (2018) 132 (Supplement 1): 2205.

https://doi.org/10.1182/blood-2018-99-113438

Published: 2018

Journal Articles

JAK2 V617F Mutation Allele Burden (MAB) and Its Correlation with Hematologic Characteristics in Myeloproliferative Neoplasms

David Y Kim, DO, Hamza Tariq, MD, Alan F Brown, MD, Kumari Vadlamudi, MT, Yao Wang, MB, Shohei Ikoma, MD, Kenneth N Holder, MD, Russell A Higgins, MD, Hongxin Fan, MD

Blood (2017) 130 (Supplement 1): 5267.

https://doi.org/10.1182/blood.V130.Suppl_1.5267.5267

Published: 2017

Journal Articles

Polyphosphate colocalizes with factor XII on platelet-bound fibrin and augments its plasminogen activator activity

Joanne L. Mitchell, Ausra S. Lionikiene, Georgi Georgiev, Anja Klemmer, Chelsea Brain, Paul Y. Kim, Nicola J. Mutch

Blood (2016) 128 (24): 2834–2845.

https://doi.org/10.1182/blood-2015-10-673285

Published: 2016

Includes: Multimedia, Supplemental data

Journal Articles

Leukemia Stem Cells Are Characterized By CLEC12A Expression and Chemotherapy Refractoriness That Can be Overcome By Targeting with Chimeric Antigen Receptor T Cells

Saad S Kenderian, MD, Marco Ruella, MD, Olga Shestova, PhD, Michael Klichinsky, PharmD, Miriam Y Kim, MD, Craig Soderquist, MD, Adam Bagg, MD, Reshma Singh, PhD, Celeste Richardson, PhD, Regina M Young, PhD, Carl H June, MD, Saar I. Gill, MD PhD

Blood (2016) 128 (22): 766.

https://doi.org/10.1182/blood.V128.22.766.766

Published: 2016

Journal Articles

Ruxolitinib Prevents Cytokine Release Syndrome after CART Cell Therapy without Impairing the Anti-Tumor Effect in a Xenograft Model

Saad S Kenderian, MD, Marco Ruella, MD, Olga Shestova, PhD, Miriam Y Kim, MD, Michael Klichinsky, PharmD, Fang Chen, PhD, Natalka Kengle, Simon Francis Lacey, PhD BS, J. Joseph Melenhorst, PhD, Carl H June, MD, Saar I. Gill, MD PhD

Blood (2016) 128 (22): 652.

https://doi.org/10.1182/blood.V128.22.652.652

Published: 2016

Journal Articles

Engineering Resistance to Antigen-Specific Immunotherapy in Normal Hematopoietic Stem Cells By Gene Editing to Enable Targeting of Acute Myeloid Leukemia

Miriam Y Kim, MD, Saad S Kenderian, MD, Daniel Schreeder, MD PhD, Michael Klichinsky, PharmD, Miroslaw Kozlowski, PhD, Olga Shestova, PhD, Marco Ruella, MD, Saar I Gill, MBBS, PhD

Blood (2016) 128 (22): 1000.

https://doi.org/10.1182/blood.V128.22.1000.1000

Published: 2016

Journal Articles

Identification of PD1 and TIM3 As Checkpoints That Limit Chimeric Antigen Receptor T Cell Efficacy in Leukemia

Saad S Kenderian, MD, Marco Ruella, MD, Olga Shestova, PhD, Michael Klichinsky, PharmD, Miriam Y Kim, MD, David L Porter, MD, Carl H. June, MD, Saar I Gill, MBBS, PhD

Blood (2015) 126 (23): 852.

https://doi.org/10.1182/blood.V126.23.852.852

Published: 2015

Journal Articles

Platelets: connecting clotting and lysis

Paul Y. Kim

Blood (2015) 125 (16): 2459.

https://doi.org/10.1182/blood-2015-03-632158

Published: 2015

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial

4D intravital imaging studies identify platelets as the predominant cellular procoagulant surface in a mouse hemostasis model

A Lenalidomide-Inducible Suicide Switch for Gene- and Cell-Based Therapy

Targeting Normal Myelopoiesis Negatively Affects CAR T Cell Activity

An “Off-the-Shelf” CD2 Universal CAR-T Therapy Combined with a Long-Acting IL-7 for T-Cell Malignancies

CXCR4 to improve both T cell homing and function

Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells

Reticulocytes Are an Unappreciated Risk Factor for RBC Alloimmunization at the Donor and Recipient Levels

Normal Myeloid Cells Are Required for Sustained CAR T Cell Activity Against Myeloid Tumor in a Humanized Mouse Model

A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma

CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas

Flotetuzumab and Other Cellular Immunotherapies Upregulate MHC Class II Expression on Acute Myeloid Leukemia Cells in Vitro and In Vivo

Chimeric Antigen Receptor T Cells Specific for CLL-1 for Treatment of Acute Myeloid Leukemia

JAK2 V617F Mutation Allele Burden (MAB) and Its Correlation with Hematologic Characteristics in Myeloproliferative Neoplasms

Polyphosphate colocalizes with factor XII on platelet-bound fibrin and augments its plasminogen activator activity

Leukemia Stem Cells Are Characterized By CLEC12A Expression and Chemotherapy Refractoriness That Can be Overcome By Targeting with Chimeric Antigen Receptor T Cells

Ruxolitinib Prevents Cytokine Release Syndrome after CART Cell Therapy without Impairing the Anti-Tumor Effect in a Xenograft Model

Engineering Resistance to Antigen-Specific Immunotherapy in Normal Hematopoietic Stem Cells By Gene Editing to Enable Targeting of Acute Myeloid Leukemia

Identification of PD1 and TIM3 As Checkpoints That Limit Chimeric Antigen Receptor T Cell Efficacy in Leukemia

Platelets: connecting clotting and lysis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only